Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
Address
ONE CAVENDISH PLACE
LONDON, X0 W1G0QF
Founded
2015
Number of Employees
33
Website
http://www.mereobiopharma.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)